Exero Medical’s prospective, blinded, multi-center study of xBar has been approved by the WCG.
| |
| [17-January-2024] |
| Enrollment to commence in Q1 2024 OR YEHUDA, Israel, Jan. 17, 2024 /PRNewswire/ -- Exero Medical’s prospective, blinded, multi-center study of xBar has been approved by the WCG.
The study, expected to commence during Q1 2024 at several leading US and Israeli hospitals, will enroll about 190 patients undergoing colorectal resection. It will evaluate the performance of Exero Medical’s flagship device, xBar, in accurately monitoring tissue healing during post-operative recovery to enable the early detection of major complications, such as anastomotic leaks, and the application of enhanced recovery protocols. This new approach to personalized care for patients undergoing gastrointestinal surgery is intended to enhance surgical outcomes and reduce hospital costs. This study follows a prior successful clinical study presented in 2023 at the SAGES’ Next Big Thing Technology Session. Prof. Patricia Sylla MD, FACS, FASCRS, System Chief of Colon and Rectal Surgery for the Mount Sinai Health System, said, “Our goal is to detect complications earlier than we do now and minimize unnecessary stays at the hospital. The xBar system can potentially provide us with a new source of data to support implementation of such enhanced recovery protocols.” Mount Sinai is among several leading medical centers planning to enroll patients in the study. Exero Medical CEO Dr. Erez Shor said, “We have developed the xBar system as a way to translate a wealth of physiological data, which has been hidden to date for the most part, into tangible, actionable clinical data. Our goal is to empower the clinical team to provide precise, personalized care on time, avoid conditions that are likely to become dire and optimize hospital stays.” About Exero Medical Exero Medical was founded in 2018 by MEDX Xelerator, an Israeli Innovation Authority incubator, and Clalit Health Services, the largest HMO in Israel. Exero Medical’s goal is to provide high-quality, actionable post-surgery tissue healing monitoring that can save lives, improve prognosis, and reduce costs. The company’s flagship product, xBar, addressing a $7B market, received FDA Breakthrough Designation and is in clinical studies towards a commercial launch in 2025. For more information, please visit https://www.exeromedical.com/ Follow Exero Medical on LinkedIn Press Contact Photo - https://mma.prnewswire.com/media/2320396/x_Bar_Exero_Medical.jpg
SOURCE Exero Medical |
View original content to download multimedia:
